Vmbook Online ordering
Biotechnology
A corporation that creates therapies for pain management and addiction treatment is called BioDelivery Sciences International, Inc. (NASDAQ: BDSI). Here are some details on BDSI's business performance, financials, and growth prospects:
Financial Overview:
In the biotech industry, BDSI concentrates on creating and selling therapies for pain management and addiction. The corporation has a strong product portfolio with two FDA-approved medications: Belbuca and Bunavail. Even though the business has grown substantially over the years, it has yet to become profitable. BDSI has further development operations for other potential medicines and therapies.
The company reported a $67.4 million net loss for 2020, compared to a net loss of $33.5 million in 2019. The increasing R&D expenses and other operational costs are largely to blame for the worsening deficit. BDSI had $23.2 million in revenue for 2020, which only showed a slight rise from the previous year.
Development and Pipeline:
BDSI is developing several medications for pain management and addiction treatment. As part of its development program, Buprenorphine Buccal Film (B Bureau), which the FDA approved in 2020 for managing opioid withdrawal symptoms, is one of the businesses that are actively being developed. For pain relief, BDSI is also developing a drug called Clonidine Topical Gel. Several studies testing the product'8s safety and efficiency are still ongoing.
Development ( pipeline)
An investor should evaluate BDSI'S prospects concerning its financial performance, pipeline development, and market possibilities. Although the company has expanded its customer base and raised revenue in recent years, it still needs to become consistently profitable. Furthermore, the biotech industry experiences unpredictability, which makes forecasting business performance challenging.
A possible investor should conduct additional research and thoughtfully consider their risk tolerance before deciding to invest in BDSI or any other company.